ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2156

Differential Item Functioning of Inflammatory Back Pain Criteria in US Subpopulations
Abstract Number: 2157

Dimensionality of Inflammatory Back Pain Criteria in the US Population
Abstract Number: 2158

An MVPA Is MVPA Is MVPA, or Is It? Impact of the Definition of Moderate to Vigorous Physical Activity (MVPA) on Its Amount in Persons with Advanced Knee Osteoarthritis
Abstract Number: 2159

Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education
Abstract Number: 2160

Development of a Lupus Chatbot
Abstract Number: 2161

Parent and Youth Report of Psychosocial Functioning in Chronic Childhood Vasculitis
Abstract Number: 2162

Exploring Barriers to Rheumatoid Arthritis Treatment Changes: Insights into Patient Concerns
Abstract Number: 2163

Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App
Abstract Number: 2164

Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase
Abstract Number: 2165

Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
Abstract Number: 2166

Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions
Abstract Number: 2167

Trust and Shared Decision-Making in Adolescents with Systemic Lupus Erythematosus: Findings from a Pilot Survey Design Study
Abstract Number: 2168

Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis
Abstract Number: 2169

Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study
Abstract Number: 2170

Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].